FactSet Survey Analysts Give Corvus Pharmaceuticals a Buy Rating

Summary

According to the FactSet survey, analysts have an average rating of ‘buy’ for Corvus Pharmaceuticals with an average price target of $15.40.Trading View

Impact Analysis

This event is classified at the company level, as it pertains specifically to Corvus Pharmaceuticals’ analyst ratings. The buy ratings indicate positive sentiment among analysts regarding the company’s future performance. This sentiment can lead to increased investor interest and potentially drive up the stock price. Supporting data shows that Corvus Pharmaceuticals had a strong Q1 2025 financial performance, with net income boosted by warrant liability adjustment gains.Reuters Additionally, HC Wainwright previously issued a buy rating with a target price of $11.00.Market Beat Despite these positive ratings, it is noted that Corvus Pharmaceuticals was not among the top five stocks recommended by top analysts, which may temper investor expectations.Market Beat Overall, the buy ratings and price targets suggest investment opportunities in Corvus Pharmaceuticals, with the potential for stock appreciation based on analyst consensus.